Life Science News

LevelJump Healthcare Corp. a Canadian leader in B2B telehealth solutions, is pleased to announce that, it has received TSXV approval, and has closed its acquisition of a 14.6% minority equity interest in Real Time Medical Inc. a private Ontario company, in exchange for 2,494,576 units of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three Leveljump common shares ...

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, it has received TSXV approval, and has closed its acquisition of a 14.6% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,494,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

"We are very excited about this investment and believe that with Real Time's teleradiology operations and servicing in multiple provinces across Canada, that there is a natural complement to our core CTS operations," said Mitchell Geisler, Chief Executive Officer of the Company. "We are focused on expanding our telehealth solutions and offering critical care radiology support and this investment is another step in growing our company."

All securities issued will be subject to a hold period of four months and one day pursuant to applicable securities laws.

About Real Time Medical

Real Time Medical is a company created by clinicians, for clinicians. Its founders include three Canadian radiologists and a former GE PACS executive. The vision is to grow and operate a nationwide radiology collaboration service for Canadian radiologists, with world class, patented diagnostic workload balancing, workflow orchestration, peer learning and diagnostic operations software. The service network was launched in 2008.

About Leveljump Healthcare

LevelJump Healthcare Corp., (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology. The Company's subsidiary, CTS, provides off-site radiology readings for hospital emergency rooms and is a leader in the teleradiology space in Ontario. As part of our growth strategy, we are acquiring healthcare companies that have strong revenue and cash flow, with room for organic growth.

ON BEHALF OF THE BOARD OF DIRECTORS OF
LevelJump Healthcare Corp.

Mitchell Geisler, Chief Executive Officer
info@leveljumphealthcare.com
(833) 840-2020

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106961

News Provided by Newsfile via QuoteMedia

Medtronic announces results showing meaningful pain relief using DTM Spinal Cord Stimulation endurance therapy

DTM™ SCS endurance therapy enables long-lasting recharge-free performance on Vanta™ and 5-minute recharge on Intellis™ neurostimulators

- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced three-month results from an on-label, prospective, multi-center study 1 showing meaningful pain relief using DTM™ SCS endurance therapy, a modified, lower-energy variation of the company's Differential Target Multiplexed™ (DTM) Spinal Cord Stimulation (SCS) therapy for chronic overall, back or leg pain. At 3 months, patients treated with DTM SCS endurance therapy reported meaningful pain relief as measured by a 3.9 cm reduction in overall pain on the 10 cm Visual Analog Scale (VAS) 2 . Patients also reported an average 4.3 cm decrease in back pain, and an average 5.0 cm decrease in leg pain.

Keep reading... Show less

Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering

- Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") announced today that, in connection with its previously announced intention to separate its eye health business, its wholly owned subsidiary, Bausch + Lomb Corporation ("Bausch + Lomb"), has publicly filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") and a preliminary base post-receipt pricing procedure ("PREP") prospectus with the securities regulatory authorities in each of the provinces and territories of Canada (other than Quebec ) ("Canadian Regulators") relating to a proposed initial public offering ("IPO") of Bausch + Lomb's common shares concurrently in the United States and Canada . All of the shares being offered will be sold by a wholly owned subsidiary of Bausch Health. The number of common shares to be offered and the price range for the IPO have not yet been determined.

Morgan Stanley and Goldman Sachs & Co. LLC are acting as joint lead book-running managers for the IPO. J.P. Morgan, Citigroup, Barclays, BofA Securities, Guggenheim Securities, Jefferies, Evercore ISI, Wells Fargo Securities and Deustche Bank Securities are acting as joint book-running managers for the IPO, and DNB Markets, HSBC and Truist Securities are acting as co-managers for the IPO.

Keep reading... Show less

Medtronic announces schedule for presentations at the 2022 North American Neuromodulation Society Meeting

Sessions will include DTM™ SCS endurance therapy 3-month outcomes for patients with chronic back and leg pain

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its schedule for presentations at the 25th Annual North American Neuromodulation Society meeting, taking place January 13-15, 2022 in Orlando, Florida . Medtronic therapies and technologies will be represented as part of 23 podium and poster presentations. The company will also welcome guests to booth #404 featuring an innovation suite and opportunities to learn from Medtronic scientists and engineers about the new Vanta™ recharge-free neurostimulator, as well as a new modified energy variation of Differential Target Multiplexed™ (DTM) Spinal Cord Stimulation known as DTM™ SCS endurance therapy. Medtronic will also showcase its targeted drug delivery options for patients with chronic pain.

Keep reading... Show less

Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms

- Abbott (NYSE: ABT) today announced it has received clearance from the U.S. Food and Drug Administration for the EnSite™ X EP System with EnSite Omnipolar Technology (OT), a new cardiac mapping platform available in the U.S. and across Europe that is designed to help physicians better treat abnormal heart rhythms, also known as cardiac arrhythmias. Designed with input from electrophysiologists from around the world, the system creates highly detailed three-dimensional maps of the heart to help physicians identify and then treat areas of the heart where abnormal rhythms originate.

"More patients than ever before are benefitting from ablation to treat abnormal heart rhythms, and Abbott's new EnSite X System with EnSite OT, utilizing Advisor HD Grid catheter, embodies the latest innovation available to support the treatment of complex and challenging cardiac arrhythmias," said Amin Al-Ahmad , M.D., a clinical cardiac electrophysiologist with Texas Cardiac Arrhythmia at St. David's Medical Center in Austin, Texas . "To continue improving outcomes for our patients, we need a system with speed, stability and accuracy. Abbott has provided us with a system that not only supports safe and effective treatment, but enhances the accuracy of maps, allowing for a clearer understanding of what is going on in the heart and what areas need to be targeted with ablation to treat arrythmias."

Keep reading... Show less

Pall Corporation's new Supralon Filter Element Advances Equipment Protection and Reduces Energy Costs

- Pall Corporation, a leader in filtration, separation and purification technology and a Danaher operating company, launched the new Supralon TM hydraulic and lube oil filter element range, a direct upgrade for Pall's Coralon ® Ultipor ® and Red1000 series filters. Supralon filter elements incorporate a new pack construction with filter media utilizing stress-resistant technology (SRT) and showcasing anti-static properties, which ultimately help protect and prolong the life of equipment in hydraulic and lube oil applications.

Keep reading... Show less

ACELYRIN Appoints Melanie Gloria as Chief Operating Officer

- ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria BSN, as the company's chief operating officer (COO). In this role, Ms. Gloria will oversee business operations across the company.

Keep reading... Show less

Latest Press Releases

Related News

×